2-(2-Methylanilino)-N-(3-pyridyl)acetamide
In a 20 mL microwave vial, o-toluidine (0.070 mL, 0.66 mmol), potassium iodide (78 mg, 0.47 mmol) and potassium carbonate (97 mg, 0.70 mmol) were dissolved in N,N-dimethylformamide (2.5 mL) and stirred for 30 minutes. To this solution 2-chloro-N-(3-pyridyl)acetamide (80 mg, 0.47 mmol) was added and the reaction was sealed and heated to 70 o C for 4 h. After this time, product formation was observed, so the reaction was concentrated and purified by flash silica chromatography (0-10% MeOH:CH 2 Cl 2 ). Product fractions were identified by LCMS and TLC analysis, and then concentrated to give an orange oil (21 mg, 19 %). 1 H NMR (600 MHz, methanol-d 4 ) δ 8.73 (d, J = 2.4 Hz, 1H), 8 .26 (dd, J = 4.8, 1.5 Hz, 1H), 8 .11 (ddd, J = 8.4, 2.4, 1.5 Hz, 1H), 7.38 (dd, J = 8.4, 4.8 Hz, 1H), 7.14 -6.89 (m, 2H), 6.64 (t, J = 7.3 Hz, 1H), 6.56 -6.40 (m, 1H), 4.00 (s, 2H), 2.24 (s, 3H). 13 
2-(o-Tolylsulfanyl)-N-(3-pyridyl)acetamide
Prepared by procedure A with o-tolylsulfanylacetic acid (80 mg, 0.44 mmol) and 3-aminopyridine (42 mg, 0.45 mmol). Product was further purified by flash silica chromatography (0-7% MeOH:CH 2 Cl 2 ). Isolated as a white solid (51 mg, 45 %).
N-(3-Pyridyl)-2-[2-(trifluoromethyl)phenoxy]acetamide
In a 20 mL microwave vial, 2-(trifluoromethyl)phenol (106 mg, 0.66 mmol), potassium iodide (78 mg, 0.47 mmol) and potassium carbonate (97 mg, 0.70 mmol) were dissolved in N,N-dimethylformamide (3 mL) and stirred for 30 minutes. To this solution, 2-chloro-N-(3-pyridyl)acetamide (80 mg, 0.47 mmol) was added and the reaction was sealed and heated to 70 o C for 24 h. The reaction was cooled to room temperature and solvent removed in vacuo. The dry residue was taken up in EtOAc (50 ml), washed with water (20 mL) and separated aqueous phase was washed with EtOAc (20 mL). The combined organics were washed with saturated brine (2 x 10 ml), dried (MgSO4) and concentrating to dryness. The crude product was then purified by normal phase chromatography (10-80 %, EtOAc:CH 2 Cl 2 ) to give the product as a white solid (81 mg, 58 %). 1 
2-(3-Methylphenoxy)-N-(3-pyridyl)acetamide
Prepared by procedure A with 3-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 3-aminopyridine (56 mg, 0.60 mmol). Product isolated as a white solid (110 mg, 75 %). 1 
2-(4-Methylphenoxy)-N-(3-pyridyl)acetamide
Prepared by procedure A with 4-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 3-aminopyridine (56 mg, 0.60 mmol). Product isolated as a white solid (110 mg, 75 %). 1 
2-(4-Fluoro-2-methylphenoxy)-N-(3-pyridyl)acetamide
In a 20 mL microwave vial, 4-fluoro-2-methylphenol (77 mg, 0.61 mmol), potassium iodide (78 mg, 0.47 mmol) and potassium carbonate (97 mg, 0.70 mmol) were dissolved in N,N-dimethylformamide (3 mL) and stirred for 30 minutes. To this solution, 2-chloro-N-(3-pyridyl)acetamide (80 mg, 0.47 mmol) was added and the reaction was sealed and heated to 70 o C for 24 h. The reaction was cooled to room temperature and solvent removed in vacuo. The dry residue was taken up in EtOAc (50 ml), washed with water (20 mL) and separated aqueous phase was washed with EtOAc (20 mL). The combined organics were washed with saturated brine (2 x 10 ml), dried (MgSO 4 ) and concentrating to dryness. The crude product was then purified by normal phase chromatography (10- 
2-(2-Methylphenoxy)-N-phenylacetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and aniline (0.06 mL, 0.61 mmol). Product was isolated as a white solid (121 mg, 83 %). 1 
2-(2-Methylphenoxy)-N-(5-methylpyrazin-2-yl)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 2-Amino-5-methylpyrazine (67 mg, 0.61 mmol). Product isolated as a white solid (63 mg, 41 %). 1 
2-(2-Methylphenoxy)-N-(1-methylpyrazol-3-yl)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 1-methylpyrazol-3-amine (64 mg, 0.66 mmol). Product isolated as a white solid (87 mg, 59 %). 
2-(2-Methylphenoxy)-N-(3-pyridylmethyl)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 3-picolylamine (0.06 mL, 0.61 mmol). Product was isolated as white solid (120 mg, 78 %). 
N-(1H-Indol-5-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 5-aminoindole (81 mg, 0.61 mmol). Product was isolated as a pale brown solid (109 mg, 65 %). 
N-(1-Methylindol-5-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 5-amino-1-methyl-1H-indole (67 mg, 0.46 mmol). Product was isolated as a light brown solid (109 mg, 82 %). 1 
N-(1-Methyl-1H-benzimidazol-6-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 6-amino-1-methyl-1H-benzimdazole (69 mg, 0.47 mmol). Product was isolated as an off-white solid (97 mg, 73 %). 
N-(2-Methylindazol-6-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 2-methylindazol-6-amine (67 mg, 0.46 mmol). Product was then further purified by normal phase chromatography (10-100 %, EtOAc:cyclohexane) and isolated as an off-white solid (95 mg, 71 %). 1 
N-(1-Ethylindazol-6-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (70 mg, 0.42 mmol) and 1-ethylindazol-6-amine (69 mg, 0.43 mmol). Product isolated as an off-white solid (110 mg, 84 %). 1 
37N-(2-Ethylindazol-6-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 2-ethylindazol-6-amine (74 mg, 0.46 mmol). Product isolated as an off-white solid (102 mg, 73 %). 1 
N-(2-Isopropylindazol-6-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (70 mg, 0.42 mmol) and 2-isopropylindazol-6-amine (74 mg, 0.42 mmol). Isolated as an off-white solid (93 mg, 68 %). 1 
N-(3H-Benzotriazol-5-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 1H-1,2,3-benzotriazol-5-amine (62 mg, 0.46 mmol). Isolated as a white solid (61 mg, 48 %). 
N-(2-Methylbenzotriazol-5-yl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 2-methylbenzotriazol-5-amine (70 mg, 0.47 mmol). Product was isolated as an off-white solid (87 mg, 65 %).
LCMS (Basic method) Rt 1.73 mins, MS m/z 297.1 [M+H]+

N-(3-Isoquinolyl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (100 mg, 0.60 mmol) and 3-aminoisoquinoline (87 mg, 0.61 mmol). Product was isolated as a yellow solid (84 mg, 48 %). 1 
N-(6-Isoquinolyl)-2-(2-methylphenoxy)acetamide
Prepared by procedure A with 2-methylphenoxyacetic acid (75 mg, 0.45 mmol) and 6-aminoisoquinoline (66 mg, 0.46 mmol). Product was further purified by normal phase chromatography (15-100 %, EtOAc:CH 2 Cl 2 ) and isolated as a white solid (47 mg, 36 %). 54 1-(3,4-Dihydro-1H-isoquinolin-2-yl)-2-(2-methylphenoxy) Preparation of NOTUM protein using HEK293S (GnTI -) stably transfected with pNeo sec-hNotum (core)
These cells constitutively express NOTUM core protein (a full functional secreted protein spanning residues 81-451 of NOTUM with mutation Cys330Ser as previously described). 1 They are G418 resistant but G418 is not needed for culture.
The HEK293S cell line was sourced from ATCC: HEK293S GnTI -(ATCC ® CRL-3022 ™ ).
Growth Media:
DMEM (High Glucose), 5mM Glutamine, 1x NEAA, 10 % FCS.
Production Media:
DMEM (High Glucose), 5mM Glutamine, 1x NEAA, 1.5 % -2 % FCS.
Culture:
Culture cells in growth media up to required quantity at 37 o C. The cells can be expanded either using corrugated roller bottles, or triple layer flasks.
For Roller Bottles -Subculture from starter culture (in stages) up to approximately 12 xT175 flasks before expanding up to 25 x Corrugated roller bottles, adding 250 mL of complete growth medium to each roller bottle. After approximately 72 hours the medium should be changed to the Production Medium. Leave for 7-10 days before harvesting.
For Triple Layer Flasks -Subculture from starter culture (in stages) up to approximately 60 xT175 flasks before expanding up to 100 x triple layer flasks, adding 170 mL of complete growth medium to each roller bottle. After approximately 72 hours the medium should be changed to the Production Medium. Leave for 10 days before harvesting.
Harvesting:
Pour off the supernatant and spin at 2000 rpm to remove cell debris. Pass through 0.22 M filter to get rid of aggregates. Use a 10K MWCO PES Membrane Filter (e.g. VivaFlow from Sartorius Cat: VF20P0) to concentrate the supernatant 10 fold. Re-filter through a 0.22 M filter to ensure sterility. Keep at +4 o C short term.
Dialysis:
Using Thermo Fisher Slide-A-Lyzer Dialysis Flasks (e.g. 2K MWCO 250 mL from Fisher Cat: 87760) the concentrated supernatant now needs to be dialysed extensively against PBS overnight (15 litres of PBS with 300 mM NaCl for each litre of media). This should be repeated once. The dialysed supernatant requires centrifugation at 2000rpm for 15 minutes and re-filtering through a 0.22 M filter to retain sterility. Keep at +4 o C short term.
Long-term storage:
Aliquot, add 10 % glycerol and store in -80 o C.
Protein purification:
NOTUM was purified from conditioned culture supernatants essentially as described. 1 In brief, the conditioned supernatant collected from a cell-line secreting 6xHis tagged NOTUM(81-451 Cys330Ser) was incubated with NiNTA resin (Qiagen) and incubated overnight at 4 °C gently rocking. Subsequently, the resin was washed 5 times with PBS before NOTUM was eluted with 250 mM imidazole. The eluate was concentrated and applied to a Superdex75 (GE Healthcare) and the NOTUM containing fractions were pooled, concentrated and snap-frozen in liquid N 2 and stored at -80 o C until used. An Echo liquid handler was used to acoustically dispense 500 nL of compounds into dry Greiner 384-well plates (catalog #781076), followed by 25 μL of 2 μM trisodium 8-octanoyloxypyrene-1,3,6-trisulfonate (OPTS, Sigma #74875) solution in 50 mM Tris, 5 mM CaCl 2 , 0.5 mM MgCl 2 , pH 7.4 assay buffer, and 25 μL of 2.38 nM NOTUM carboxyesterase enzyme solution in the same buffer to every well in the assay plate. After 1 hour incubation at room temperature, fluorescence was measured on a PheraSTAR FSX microplate reader with an excitation wavelength of 485 nm and emission wavelength of 520 nm. TCF/LEF reporter (Luciferase) cell based assay 20 L of TCF LEF cells were plated in 384 well cell culture Greiner microplates (catalog #781098) at 10,000 cells per well and incubated overnight at 37 o C. An Echo liquid handler was used to acoustically dispense 150 nL of compounds into V-well polypropylene Greiner microplate (catalog #781280) to create a 10 point curve. 25 L of 0.5 % DMEM media (500 mL DMEM 1X GlutaMax, 4.5 g/L D-Glucos, Pyruvate plus 2.5 mL 10 % Fetal Bovine Serum and 5 mL Penicillin Streptomycin) was added to the Wnt compound plates and 25 L of NOTUM at 1000 g/mL was added to the NOTUM compound plates and incubated at room temperature for 10 minutes. 25 L of Wnt-3A at 200 ng/mL was added to all plates and incubated at room temperature for 1 hour. 20 L of media was aspirated from the cell plates using a CyBio SELMA followed the addition of 40 L from the compound plates. After an overnight incubation at 37 o C GFP fluorescence was measured on a PHERAstar FSX microplate reader with a wavelength of 458 nm and emission wavelength of 520 nm. 20 L of steady-glo luciferase assay buffer (Promega #E2520) was added to the cell plates using the CyBio, the luminescence was measured on the PHERAstar. 
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Dose-response curve analysis:
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In vitro ADME screens Selected compounds were screened for aqueous solubility, transit performance in MDCK-mdr1 cell lines for permeability, and metabolic stability in human and mouse liver microsomes as a measure of clearance. ADME studies reported in this work were independently performed by GVK Biosciences (Hyderabad, India) and/or Cyprotex (Macclesfield, UK).
Cyptotex, UK. See: https://www.cyprotex.com/admepk GVK Biosciences, India. See: https://www.gvkbio.com/discovery-services/biology-services/dmpkservices/
The MDCK-mdr1 cell line used in these experiments was supplied to GVK Biosciences from SOLVO Biotechnológiai ZRT. 
